Source:http://linkedlifedata.com/resource/pubmed/id/11169953
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2001-2-22
|
pubmed:abstractText |
We investigated the effect of hepatocyte-derived extracellular matrix (ECM) on the expression of erb-B2 and erb-B3 in colon cancer cell lines, as well as the role of erb-B2 and erb-B3 in colon cancer cell proliferation. Colon cancer cell lines plated on hepatocyte-derived ECM had increased protein levels of both erb-B2 and erb-B3. The addition of soluble recombinant proteoglycan syndecan-4 also resulted in higher expression of erb-B2 and erb-B3. We prepared hepatocyte-derived ECM from 1 to 7 days' cultures of hepatocytes, which contained different amounts of sulfated glycosaminoglycans. There was a direct correlation between the amounts of sulfated glycosaminoglycans in the ECM and the levels of erb-B2 and erb-B3 in the colon cell line KM12. The stimulatory effect of hepatocyte-derived ECM was abolished when the colon cancer cells were cultured in the presence of antibodies to erb-B2. These studies show that hepatocyte-derived ECM and the heparan sulfate proteoglycans present in it are responsible for inducing erb-B2 and erb-B3 in colon cancer cells. The growth stimulatory effect of extracellular matrix is mediated, at least in part, by increased expression of erb-B2 and erb-B3.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Heparan Sulfate Proteoglycans,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proteoglycans,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-3,
http://linkedlifedata.com/resource/pubmed/chemical/SDC4 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Syndecan-4
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0020-7136
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
91
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
316-21
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:11169953-Antibodies, Monoclonal,
pubmed-meshheading:11169953-Cell Division,
pubmed-meshheading:11169953-Colonic Neoplasms,
pubmed-meshheading:11169953-Extracellular Matrix,
pubmed-meshheading:11169953-Heparan Sulfate Proteoglycans,
pubmed-meshheading:11169953-Humans,
pubmed-meshheading:11169953-Membrane Glycoproteins,
pubmed-meshheading:11169953-Proteoglycans,
pubmed-meshheading:11169953-Receptor, erbB-2,
pubmed-meshheading:11169953-Receptor, erbB-3,
pubmed-meshheading:11169953-Syndecan-4,
pubmed-meshheading:11169953-Tumor Cells, Cultured
|
pubmed:year |
2001
|
pubmed:articleTitle |
Soluble and matrix-associated heparan sulfate proteoglycans increase expression of erb-B2 and erb-B3 in colon cancer cell lines.
|
pubmed:affiliation |
Liver Metastasis Research Group, Gastroenterology Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. isab@tasmc.health.gov.il
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|